Gilead Sciences, Inc. - Product Pipeline Review - H2 2011

Description: Gilead Sciences, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct's pharmaceuticals report, “Gilead Sciences, Inc. - Product Pipeline Review - H2 2011” provides data on the Gilead Sciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Gilead Sciences, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Gilead Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Gilead Sciences, Inc. - Brief Gilead Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Gilead Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Gilead Sciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Gilead Sciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Gilead Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Gilead Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Gilead Sciences, Inc.; Gilead Sciences, Inc. - Key Therapeutics; Gilead Sciences, Inc. - Pipeline Overview and Promising Molecules; Gilead Sciences, Inc. - News; Gilead Sciences, Inc. - Latest Updates; Gilead Sciences, Inc. - Pipeline; Gilead Sciences, Inc. - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
Gilead Sciences, Inc. Snapshot
Gilead Sciences, Inc. Overview
Gilead Sciences, Inc. – Research and Development Overview
Gilead Sciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Gilead Sciences, Inc. – Pipeline Products Glance
Gilead Sciences, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Gilead Sciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Gilead Sciences, Inc. – Drug Profiles
Aztreonam
Product Description
Mechanism of Action
R&D Progress
CAL-263
Product Description
Mechanism of Action
R&D Progress
Cicletanine
Product Description
Mechanism of Action
R&D Progress
Cobicistat
Product Description
Mechanism of Action
R&D Progress
Complera
Product Description
Mechanism of Action
R&D Progress
GS 1101
Product Description
Mechanism of Action
R&D Progress
GS 1101 + Bendamustine
Product Description
Mechanism of Action
R&D Progress
GS 1101 + Bendamustine + Rituximab
Product Description
Mechanism of Action
R&D Progress
GS 1101 + Fludarabine
Product Description
Mechanism of Action
R&D Progress
GS 1101 + Ofatumumab
Product Description
Mechanism of Action
R&D Progress
GS 1101 + Rituxan
Product Description
Mechanism of Action
R&D Progress
GS 5885
Product Description
Mechanism of Action
R&D Progress
GS 5885 + GS 9190 + Pegasys + Copegus
Truvada + Hepatitis B Immunoglobulin
Product Description
Mechanism of Action
R&D Progress
Gilead Sciences, Inc. – Pipeline Analysis
Gilead Sciences, Inc. – Pipeline Products by Therapeutic Class
Gilead Sciences, Inc. - Pipeline Products By Target
Gilead Sciences, Inc. – Pipeline Products by Route of Administration
Gilead Sciences, Inc. – Pipeline Products by Molecule Type
Gilead Sciences, Inc. – Recent Pipeline Updates
Gilead Sciences, Inc. - Dormant Projects
Gilead Sciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Ambrisentan
BI 224436
Darusentan
GS 9005
GS 9132
GS 9219
GS 9411
GS 9450
MKC-442 + Non-Nucleoside Reverse Transcriptase Inhibitors
MKC-442 + Stavudine + Didanosine + Hydroxyurea
Perfan
Gilead Sciences, Inc. – Company Statement
Gilead Sciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 27, 2011: Gilead Submits New Drug Application To FDA For Once-Daily, Single-Tablet "Quad" HIV Regimen
Apr 27, 2011: Gilead Finalizes Selection Of Bioequivalent Formulation For Fixed-Dose Regimen Of Truvada And Tibotec's TMC278
Jan 25, 2011: Gilead Sciences Receives Refuse To File Notification From FDA On New Drug Application For Single-Tablet Regimen Of Truvada And TMC278
Sep 23, 2011: Tibotec Announces EDURANT Receives Positive Opinion From CHMP For Use In Treatment-Naive Adults With HIV-1
Sep 19, 2011: Gilead's Second Pivotal Phase III Clinical Study Of Quad Regimen Meets 48-Week Primary Objective
Apr 18, 2011: FHI To Initiate Orderly Closure Of Truvada African FEM-PrEP Clinical Trial
Aug 15, 2011: Gilead's Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective In Pivotal Phase III Clinical Study 102
Apr 12, 2011: Gilead Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily 'Quad' Regimen For HIV
Aug 10, 2011: Gilead Sciences Receives FDA Approval For Complera For HIV-1 Infection In Treatment-Naïve Adults
Feb 10, 2011: Gilead Sciences Refiles New Drug Application With FDA For Single-Tablet Regimen Of Truvada And TMC278
Nov 07, 2011: Gilead Sciences And Cardiovascular Research Foundation Initiate Phase III Trial With Ranolazine in Chronic Angina Patients
Feb 07, 2011: Gilead Sciences Announces Notification Of ANDA Filing For Tamiflu
Nov 05, 2011: Gilead Announces Positive Five-Year Data Showing Effect Of Viread On Liver Fibrosis And Cirrhosis Caused By Chronic Hepatitis B
Sep 04, 2011: Gilead Amends Study Design For Ongoing Hepatitis Study That Includes GS 9190, Pegylated Interferon And Ribavirin, And Another Direct-Acting Antiviral Agent
Sep 04, 2011: Gilead Amends Study Design For Ongoing Hepatitis Study That Includes GS 9190, Pegylated Interferon And Ribavirin, And Another Direct-Acting Antiviral Agent
Mar 04, 2011: FDA Removes Warning About Potential Liver Injury From Boxed Warning Of Prescribing Information For Gilead's Letairis
May 03, 2011: AHF's Board Opposes FDA-approval Of Gilead's AIDS Drug Truvada As HIV Prevention
Apr 01, 2011: Yuhan Enters Into Licensing Agreement With Gilead Sciences For Viread
Financial Deals Landscape
Gilead Sciences, Inc., Deals Summary
Gilead Sciences, Inc., Pharmaceuticals & Healthcare, Deal Details

Asset Transactions
Gilead Sciences To Acquire Oceanside Clinical Plant From Genentech
Gilead Sciences And Royalty Pharma Acquire Royalty Interest Of Emtriva From Emory University

Venture Financing
Achillion Pharmaceuticals Raises $35 Million In Series C2 Financing

Partnerships
Gilead Sciences Completes Public Offering Of Senior Unsecured Notes Due 2021 For $1,000 Million
Gilead Sciences Completes Private Placement Of 1% Senior Notes For $1,100 Million
Gilead Sciences Completes Private Placement Of 1.625% Senior Notes For $1,100 Million
Gilead Sciences Completes Private Placement Of Convertible Senior Notes Due 2011 For $650 Million
Gilead Sciences Completes Private Placement Of Convertible Senior Notes Due 2013 For $650 Million

Asset Transactions
Graceway Pharmaceuticals Acquires Licensing Rights From Gilead Sciences

Acquisition
Gilead Sciences Acquires Calistoga Pharmaceuticals
Gilead Sciences Acquires Arresto Biosciences
Gilead Sciences Acquires CGI Pharmaceuticals
Gilead Sciences Acquires CV Therapeutics
Gilead Sciences Acquires Navitas Assets
Gilead Sciences Acquires Nycomed Limited
Gilead Sciences Acquires Myogen
Gilead Sciences Acquires Raylo Chemicals From Degussa
Gilead Sciences Acquires Corus Pharma
Myogen Sells Its European Subsidiary To Wulfing Holding

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Gilead Sciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Gilead Sciences, Inc. – Pipeline by Stage of Development, H2 2011
Gilead Sciences, Inc. – Filed, H2 2011
Gilead Sciences, Inc. – Phase III, H2 2011
Gilead Sciences, Inc. - Phase II, H2 2011
Gilead Sciences, Inc. - Phase I, H2 2011
Gilead Sciences, Inc. - Pipeline By Therapeutic Class, H2 2011
Gilead Sciences, Inc. - Pipeline By Target, H2 2011
Gilead Sciences, Inc. - Pipeline By Route of Administration, H2 2011
Gilead Sciences, Inc. - Pipeline By Molecule Type, H2 2011
Gilead Sciences, Inc. - Recent Pipeline Updates, H2 2011
Gilead Sciences, Inc. - Dormant Developmental Projects, 2010
Gilead Sciences, Inc. - Discontinued Pipeline Products, 2010
Gilead Sciences, Inc., Other Locations
Gilead Sciences, Inc., Subsidiaries
Gilead Sciences, Inc., Deals Summary
Gilead Sciences To Acquire Oceanside Clinical Plant From Genentech
Gilead Sciences And Royalty Pharma Acquire Royalty Interest Of Emtriva From Emory University
Achillion Pharmaceuticals Raises $35 Million In Series C2 Financing
Gilead Sciences Enters Into Licensing Agreement With CONRAD And IPM
Gilead Sciences Enters Into Research Collaboration With Yale School of Medicine
Selcia Enters Into Collaboration With Gilead Sciences
Gilead Sciences Enter Into An Agreement With Merck
Gilead Sciences Enters Into Research Collaboration With Gladstone Institute
Gilead Sciences Enters Into An Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb And Gilead Sciences Enters Into An Agreement For ATRIPLA
Gilead Sciences Enters Into Distribution Agreement With Merck & Co.
Myogen Extends Research Agreement With Novartis Institutes for BioMedical Research
Myogen Sells Its European Subsidiary To Wulfing Holding

List of Figures
Gilead Sciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Gilead Sciences, Inc. – Pipeline by Stage of Development, H2 2011
Gilead Sciences, Inc. – Pipeline By Therapeutic Class, H2 2011
Gilead Sciences, Inc. - Pipeline By Target, H2 2011
Gilead Sciences, Inc. – Pipeline By Route of Administration, H2 2011
Gilead Sciences, Inc. – Pipeline By Molecule Type, H2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1964406/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Gilead Sciences, Inc. - Product Pipeline Review - H2 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/1964406/">http://www.researchandmarkets.com/reports/1964406/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6I18WF</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>USD 500</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 500</td>
<td>USD 1000</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 1000</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td>USD 1500</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________________________
Organisation: _______________________________________
Address: _______________________________________
City: _______________________________________
Postal / Zip Code: ___________________________
Country: _______________________________________
Phone Number: ___________________________________
Fax Number: ___________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World